莫比茨II型二度心房静脉阻塞:一种经常被过度诊断和误解的心律失常
S Serge Barold1, Bengt Herweg2
1Department of Medicine, University of Rochester University School of Medicine and Dentistry, Rochester, NY, United States.
Frontiers in cardiovascular medicine
|September 13, 2024
概括
莫比茨II型二度心房阻塞 (AVB) 的特征是具有一致PR间隔的非导电P波. 正确识别的Mobitz II型AVB需要起器,因为它来自他的Purkinje系统.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 莫比茨II型二度心房阻塞 (AVB) 呈现为失败导电的心电图案.
- 关键的诊断特征包括在非导 P 波之前和之后的一致的 PR 间隔.
- 区分Mobitz II类型与其他AVB类型对于患者管理至关重要.
研究的目的:
- 阐明莫比茨II型AVB的诊断标准.
- 为了区分Mobitz II型AVB与模仿它的条件.
- 要强调Mobitz II型AVB的临床意义和管理影响.
主要方法:
- 电心图形分析莫比茨II型AVB的电心图形分析.
- 与其他心房阻塞亚型的比较 (例如,温克巴赫,2:1 AVB).
- 考虑混因素,如鼻腔频率稳定性和外吸血.
主要成果:
- 区块后不变的PR间隔是莫比茨II型AVB的一个决定性特征.
- 2:1 AVB不能被确定为I型或II型.
- 稳定的鼻率至关重要,以排除模仿莫比茨II型的阴道效应.
- 非典型的温克巴赫和隐藏的外可被错误地诊断为莫比茨II型.
结论:
- 莫比茨II型AVB起源于希斯-普尔金耶系统.
- 准确诊断Mobitz II型AVB是一种适用于心脏起器植入的指示.
- 了解差异诊断可以防止错误分类和不适当的管理.
更多相关视频
相关概念视频
Mechanism of Cardiac Arrhythmias
900
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
900
Disturbances in Heart Rhythm
918
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
918
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
195
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
195
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
933
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
933
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
796
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
796


